Participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications when clinically indicated, and should be under the care of a physician experienced in HIV management; participants will be eligible regardless of antiretroviral medication (including no antiretroviral medication) provided there is no intention to initiate therapy or the regimen has been stable for at least  weeks with no intention to change the regimen within  weeks following enrollment
Participants are required to be on antiretroviral regimens that are in accordance with the current International Acquired Immune Deficiency Syndrome (AIDS) Society guidelines concurrently with chemotherapy; the specific agents are at the discretion of the investigator and the use of investigational agents currently available on an expanded access basis is allowed; use of experimental antiretroviral agents or those containing zidovudine (including Combivir and Trizivir) or ritonavir (includes Norvir or Kaletra), cobicistat, didanosine (Videx or Videx EC), or similar potent cytochrome P (CYP) inhibitors are prohibited; in order to be eligible, participants taking zidovudine or ritonavir, or cobicistat, didanosine, or other CYP inhibitors must change to a different regimen  days prior to therapy initiation; changes to HAART therapy during the study may be made if medically necessary (toxicity, failure of regimen, etc.); participants must be on HAART at least  days prior to therapy
Has received prior cisplatin- or carboplatin-based chemotherapy regimen for malignancy including diagnoses other than germ cell tumor
Patients must be considered reliable enough to comply with the medication regimen and follow-up, and have social support necessary to allow this compliance
Eligible for CHOP regimen
At least  prior chemotherapy regimen
More than one prior chemotherapy-containing line(re-challenge with the same initial regimen is not allowed)
All participants must be prescribed combination antiretroviral therapy with the goal of virological suppression using an acceptable regimen that adheres to national guidelines for treatment of HIV infection; non-suppressed, treatment experienced patients, defined as patients with a viral load >  copies/mL who have been on antiretroviral therapy for more than  months can be enrolled if an alternative antiretroviral therapy (ART) regimen is available that includes at least two ART drugs that, in the opinion of the site investigator, are expected to have activity based on genotypic testing (if available) and treatment history; patients are not allowed to receive zidovudine (azidothymidine [AZT]) as part of concurrent chemotherapy and ART regimen, since it is myelosuppressive; zidovudine may be discontinued and substituted as clinically indicated prior to or at the time of enrollment
Patients may not have progressed on more than two chemotherapy regimens in the metastatic setting; the following will NOT be counted as a prior line of cytotoxic chemotherapy:\r\n* If a patient discontinued a cytotoxic regimen due to toxicity (e.g., hypersensitivity or neuropathy) but had not progressed on that regimen, or if a prior chemotherapy regimen was discontinued after response achieved, it will not be counted in the number of prior chemotherapy regimens allowed\r\n* Prior hormonal therapy and non-hormonal targeted therapy; including the combination of an aromatase inhibitor and everolimus\r\n* Targeted and biologic therapies\r\n* The patient can receive a stable dose of bisphosphonates or denosumab for bone metastases, before and during the study as long as this was started at least  days prior to study treatment
Patients with histologically confirmed advanced solid tumors (regimen A) or breast or pancreas (regimen B)
Total carmustine (BCNU) dose of >  mg/m^ with prior treatments including transplant conditioning regimen
a) Active Disease () Clinically suspected or documented relapse/progression, in first or second relapse following at least one cycle of an asparaginase-based chemotherapy regimen OR () Initial disease or first or second relapse and unable to tolerate one full cycle of asparaginase-based chemotherapy regimen OR b) High-risk disease (stage III/IV, KPI groups - or IPI intermediate-high) prior to second CR regardless of previous chemotherapy.
Patients with exocrine pancreatic adenocarcinoma must have predominant adenocarcinoma histology. Patients must have received prior therapy with a gemcitabine-based or FU-based regimen, if eligible, and should have received no more than  systemic regimen in the unresectable or metastatic setting.
Participant has received more than one prior chemotherapy regimen for metastatic disease.
Ability to be off prednisone and other immunosuppressive drugs for at least  days prior to the NK cell infusion (excluding preparative regimen pre-meds)
Part , Cohort , Must have received ?  prior treatment regimen for ovarian cancer, at least  of which is a platinum-based regimen
Patients may have received - prior chemotherapeutic regimen for metastatic breast cancer and must have been off treatment with chemotherapy for at least  days before enrollment in the study; the number of patients with  prior chemotherapeutic regimen will be limited to a maximum of n = 
Participating participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications, when clinically indicated and should be under the care of a physician experienced in HIV management; participants will be eligible regardless of antiretroviral medication (including no antiretroviral medication) provided there is no intention to initiate therapy or the regimen has been stable for at least  weeks with no intention to change the regimen within  weeks following study entry; as study-specific (antiretroviral-based) strata fill, however, only participants who are receiving the therapies eligible for the remaining open strata will be accrued
Patients must have received at least one cycle of the cytotoxic chemotherapy regimens (or regimen of similar intensity) listed in Appendix D within  months of enrollment (measured from the start date of chemotherapy) OR have had an autologous transplant within  months of enrollment OR receive  cGy as part of the preparative regimen
Must have previously received and progressed on at least  prior chemotherapy regimen.
Prior regimen within  months
Prior regimen must be within  months of registration
Subjects must have relapsed after at least one prior purine analogue-containing regimen (fludarabine, cladribine or pentostatin), OR at least two non-purine analogue containing regimens
Prior therapy:\r\n* Patients may have received unlimited prior treatment for the dose escalation part\r\n* For the expansion cohort patients must have ?  prior lines of chemotherapy\r\n* Hormonal therapy does not count towards total lines of therapy\r\n* Maintenance therapy is considered part of the preceding regimen if one or more of the same drugs are continued\r\n* Neoadjuvant and adjuvant chemotherapy are considered one regimen if they are a continuation of the same regimen with interval debulking surgery
Patients may not have received more than  prior regimens, where the regimen intent was to induce remission
Patients must have received at least one prior therapy for CLL comprised of the following:\r\n* ?  regimen containing an anti-CD antibody (e.g., rituximab, obinutuzumab) administered for ?  doses\r\n* ?  regimen containing ?  cytotoxic agent (eg, bendamustine, fludarabine, chlorambucil, cyclophosphamide) administered for ?  cycles
Subjects must have relapsed or refractory non-Hodgkin lymphoma treated with at least two lines of therapy. Disease must have either progressed after the last regimen or presented failure to achieve partial or complete remission with the last regimen.
Presence of measurable AML that has progressed during or relapsed after prior therapy, including ? regimen containing a FLT kinase inhibitor.
Have stable disease or progression on a prior regimen containing infusional -FU or capecitabine according to the interpretation of the treating provider
No limit to the number of prior chemotherapy or endocrine therapy regimens received; use of a previous fluoropyrimidine-containing regimen in advanced/metastatic setting is permitted as long as the subject discontinued the regimen for reasons other than progression
Patient has used capecitabine in a past regimen for metastatic disease
Letrozole combination cohort (L): metastatic breast cancer (MBC) with progression who are candidates for a letrozole-containing regimen, with palbociclib.
Fulvestrant combination cohort (F): MBC with progression who are candidates for a fulvestrant containing regimen, with palbociclib.
Patient must receive the following medical regimen as part of standard of care immunoprophylaxis for GvHD in either study arm at doses and regimen determined by local institutional guidelines, physician preference, and patient need: MTX or MMF + calcineurin inhibitor (CSA or TAC) +/- ATG (ATG use is limited to % of patients).
Patients must be considered candidates for intensive chemotherapy treatment with standard doses of cytarabine and anthracycline regimen (+ regimen)
For advanced (stage III/IV) Hodgkin disease, patients must have failed an Adriamycin containing regimen (adriamycin-bleomycin-vinblastine-dacarbazine [ABVD]) or an alternative non-cross resistant regimen (e.g. mustargen-oncovin-procarbazine-prednisone [MOPP])
DONOR: Is approved and completed evaluation prior to recipient initiation of the preparative regimen per institutional guidelines
There will be no limit to number of prior myelosuppressive regimen for GIST or other tumor manifestations associated with NF
Experienced progression following a regimen containing an alkylating agent.
In the opinion of the treating investigator, patients must be an unsuitable candidate for a pediatric-inspired regimen, reasons for which may include (but not be limited to) older age (i.e., >=  years), practical/logistical barriers to or toxicity concerns from administration of a pediatric-inspired regimen, or Ph+ disease
Prior therapy with a chimeric antigen receptor (CAR) T-cell containing regimen.
Previous treatment with any weekly taxane regimen.
Has evidence of progression on or after the last regimen received:
Patients underwent >=  prior chemotherapy-based or immunotherapy-based regimen or targeted therapy (e.g., inhibitors of BTK, PIK etc.) administered for >=  cycles, and have had either documented disease progression or no response (stable disease) to the most recent treatment regimen
Prior treatment with a Wee inhibitor or any irinotecan containing regimen
More than one systemic therapy regimen of any type for metastatic or locally advanced disease; adjuvant gemcitabine that ended more than  months prior to diagnosis of recurrent disease is not considered as a regimen
Incurable cervical or anal cancer, as defined by:\r\n* Relapsed or progressive disease at the primary site and/or regional lymph nodes after initial treatment (e.g. systemic chemotherapy) with no potentially curative option (i.e. surgery or chemoradiotherapy); chemotherapy administered in conjunction with primary radiation as a radiosensitizer will not be counted as a systemic chemotherapy regimen; OR\r\n* Distant metastasis refractory to initial treatment (at least one prior chemotherapeutic regimen which can include a single chemotherapeutic, a combination of chemotherapeutics, or biologic drugs); cervical cancer subjects with distant metastases will have received and failed bevacizumab prior to enrollment onto the trial
Prior treatment with at least one standard chemotherapy regimen or targeted agent prior to enrollment
Patients that have received a chemotherapy regimen with stem cell support in the previous  months
Treatment with other chemotherapy regimen within the past  weeks
Participants must have received at least one prior chemotherapy regimen for their disease
Concurrent systemic high-dose corticosteroids when used intermittently in an antiemetic regimen, for central nervous system (CNS) metastases management, or as a part of the premedication regimen are allowed
Left ventricular ejection fraction of at least % (myeloablative regimen , reduced intensity regimen )
Pulmonary function test (PFT) demonstrating an adjusted diffusion capacity of least % predicted value for hemoglobin concentration (myeloablative regimen , reduced intensity regimen )
Serum glutamate pyruvate transaminase (SGPT)/bilirubin < to . x normal (myeloablative regimen ), reduced intensity regimen ; SGPT/bilirubin < to . x normal (nonmyeloablative regimen )
Meets one of the following criteria: Is currently on a stable regimen of an oral contraceptive containing mg NE and .mg EE, or Is willing to switch to a regimen of an oral contraceptive containing mg NE and .mg EE from a stable regimen of an alternate OC, or Is willing to start a regimen of an oral contraceptive containing mg NE and .mg EE.
Patients must have received at least  prior regimen
Any other condition that, according to the investigator, may forbid the administration of the idarubicin + cytarabine regimen
Patients who have received more than  prior therapy; NOTE: Prior therapy is defined as any single agent or combination regimen that is included as treatment for symptomatic CLL; treatment(s) given prior to the symptomatic phase of the disease (preventive strategy) will not be considered as prior induction therapy; for the purpose of a particular therapy/regimen to be counted towards the number of prior treatments a patient must have received at least  cycles of the induction regimen e.g., a patient who change their treatment regimen after only  cycle (due to toxicity or any other reason) will not be considered to have \\ prior therapies
At least  prior chemotherapy regimen containing cisplatin or carboplatin
Patients that have received a chemotherapy regimen with stem cell support in the previous  months
Concurrent systemic high-dose corticosteroids when used intermittently in an antiemetic regimen for central nervous system (CNS) metastases management or as a part of the premedication regimen are allowed
Patients may not have received more than  prior regimens, where the regimen intent was to induce remission
Phase II: patients are eligible if their previous chemotherapy regimen did not contain bortezomib, carfilzomib, or other known proteasome inhibitor or a combination of gemcitabine >=  mg/m^ plus adriamycin >=  mg/m^; patients who receive sequential or alternating therapy as part of front-line treatment will be counted as having one prior regimen; patients who have failed prior neoadjuvant chemotherapy will be eligible for this trial
ARM  SALVAGE COHORT: Patients with AML who have failed up to one prior salvage therapy (i.e. salvage  or  status) will be eligible for Arm  relapse cohort; allogeneic stem cell transplant for patients in remission at the time of stem cell transplant will not be considered a salvage regimen; similarly, hydroxyurea if used alone will not be considered a salvage regimen
Prolymphocytic leukemia (PLL) T-cell (T)-CLL\r\n* T-PLL: treatment failure after Campath-H and at least one other regimen\r\n* B-PLL: treatment failure after fludarabine and at least one other salvage regimen
Burkitt or lymphoblastic lymphomas\r\n* High-risk disease in remission\r\n* Progression after >=  previous regimen\r\n* Non-CR after salvage regimen
Able to initiate study treatment no later than  weeks from last dose of any antineoplastic component of prior therapy regimen
Participants for the phase  portion of the study must, in addition, meet the following: o Must be refractory to or relapsed after no more than  prior chemotherapy regimens. Re-induction with the same regimen or stem cell transplant will not be considered a separate regimen.
Cytarabine containing regimen in excess of  g/m^/day within  months of study entry
Patients with systemic infections and/or organ dysfunction mandating a reduced intensity conditioning regimen are also excluded
If younger than , there must be comorbidities which preclude the patient to undergo cyclophosphamide (Cy) TBI conditioning regimen
More than one prior systemic therapy regimen for metastatic pancreatic cancer (radiosensitizing doses of -FU or gemcitabine at the time of initial radiotherapy do not count as a prior systemic therapy regimen)
Patients that have received a chemotherapy regimen with stem cell support in the previous  months
Patients that have received a chemotherapy regimen with stem cell support in the previous  months
Patients with more than one prior chemotherapy regimen for management of primary disease
Detectable tumor prior to mobilization regimen
Have received at least one prior chemotherapy regimen for SCLC
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Must be refractory to fludarabine (fludarabine phosphate) or fail to have a complete or partial response after therapy with a regimen containing fludarabine (or another nucleoside analog, e.g. cladribine [-CDA], pentostatin) or experience disease relapse within  months after completing therapy with a regimen containing fludarabine (or another nucleoside analog)
Patients who have undergone an autologous transplant >  months prior to allogeneic transplantation and who have not received multi-agent or immunosuppressive chemotherapy within the preceding  months must receive anti-thymocyte globulin (ATG) as part of the preparative regimen
Has had prior therapy with more than one cytotoxic chemotherapy regimen NOTE: Treatment with maintenance therapy after initial chemotherapy will not be considered a separate regimen and will be allowed.
Participants must be considered by their physician eligible to receiving the IRD regimen.
Previously treated with not more than  doublet or triplet regimen and that regimen contained gemcitabine and a platinum agent
Patients who have been treated with more than one chemotherapy regimen, immunotherapy regimen or chemotherapy/immunotherapy regimen for metastatic non-small cell lung cancer
Patients that have received a chemotherapy regimen with stem cell support in the previous  months
Received at least one prior treatment regimen;historically documented CD-positivity is acceptable;
Patients with MCL underwent >=  chemoimmunotherapy-based regimen; patients with FL and MZL underwent >=  prior chemotherapy-based and/or immunotherapy-based regimen; patients with DLBCL and CLL in Richters transformation underwent >=  chemoimmunotherapy-based regimen and are not transplant-eligible; patients with CLL, B-PLL and LPL underwent >=  chemotherapy-based, or immunotherapy-based or targeted therapy regimen (e.g., PIK inhibitors [idelalisib], venetoclax, ibrutinib or an investigational agent, including an investigational BTK inhibitor); all regimens must have been administered for >=  cycles, and patients must have had either documented disease progression or no response (stable disease) to the most recent treatment regimen
More than one prior taxane regimen at any stage of the disease under study (taxane refers to paclitaxel, docetaxel, abraxane and cabazitaxel); adjuvant and/or neoadjuvant treatments are considered together as one prior regimen
May have received  prior biologic regimen (i.e. avastin) but not within  weeks of enrollment
High dose TBI regimen:  to =<  years
Intermediate intensity regimen:  =<  years
The regimen under study must constitute a reasonable therapeutic option
No more than one prior chemotherapy regimen for advanced or metastatic breast cancer is allowed; prior chemotherapy for metastatic disease must have been completed >=  days prior to randomization\r\n* Any single agent therapy, and any combination of cytotoxic, endocrine, biological targeted agents, and/or humanized antibodies, scheduled to be administered as a preplanned treatment, given concomitantly, sequentially or both, is considered one regimen\r\n* Planned neoadjuvant chemotherapy and postoperative adjuvant chemotherapy is considered one regimen\r\n* If the dosing of one or more of the chemotherapy components of a regimen must be reduced for toxicity, the modified version of the original regimen is not considered a new regimen\r\n* If one or more of the chemotherapy components of a regimen must be omitted for toxicity, the modified version of the original regimen is not considered a new regimen\r\n* If one of the chemotherapy components of a regimen must be replaced with another similar drug of the same therapeutic class, the modified version of the original regimen is not considered a new regimen; however, if a new component, dissimilar to any of the original components, is added to the regimen, the modified version is considered a new regimen\r\n* If chemotherapy is interrupted for surgery or radiotherapy and then continues with an unchanged schedule and components, treatment is considered as one regimen despite the interruption
HIV seropositive participants must be on antiretroviral therapy (ART) with the following criteria:\r\n* A complete ART regimen that does not include the study drug as one of a minimum of  active drugs, which may include an integrase inhibitor or efavirenz in combination with nucleoside reverse-transcriptase inhibitors (NRTIs)\r\n* The ART regimen must not include protease inhibitor (PIs); participants must not have received a PI-based regimen for at least  weeks prior to enrollment\r\n* Participants must either have an undetectable HIV plasma ribonucleic acid (RNA), or if plasma RNA detectable, must be on the same stable regimen for a minimum of  weeks prior to study enrollment\r\n* No minimum cluster of differentiation (CD) count, but maximum HIV plasma RNA of , copies/mL
One prior regimen/line of a taxane-containing regimen for mCRPC or refusal or ineligibility of a taxane-containing regimen
Patients must have been pretreated for advanced disease - the number of prior systemic therapy/regimen depends on which origin for NET and for GEP-NEC
Patients must be considered reliable enough to comply with the medication regimen and follow-up, and have social support necessary to allow this compliance
Patients must have received <  lines of prior therapy and have relapsed less than a year from their last platinum regimen; regimens that are used twice (for example carboplatin and paclitaxel) can be counted as one; if a regimen is changed during the course of treatment due to side effect profile or allergy, the course of therapy is counted as one regimen; (for example, if docetaxel is substituted for paclitaxel due to a reaction during the initial course of adjuvant therapy, this is considered one regimen)
More than  prior chemotherapy regimens for the current malignancy; full dose chemotherapy used in conjunction with concurrent radiation therapy will be included as prior therapy\r\n* Note: Prior hormonal therapy (e.g. leuprolide, aromatase inhibitors, tamoxifen) and immunotherapy will be allowed and not included as a prior chemotherapy; if the chemotherapy regimen is altered during the course due to issues with tolerability or safety, the regimen will be counted as one; using the same regimen at recurrence is counted as one regimen; the addition of bevacizumab to a prior regimen is considered one regimen
Stable, continuous antiretroviral treatment for at least three months before enrollment, defined as a multi-drug regimen (excluding azidothymidine [AZT])
At least  days must lapse between last prior anti-cancer treatment and st day of preparative regimen
A treatment regimen containing cytotoxic agents (eg, fludarabine, pentostatin, cladribine, cyclophosphamide, chlorambucil, bendamustine) AND
Disease specific therapies within  week of starting conditioning regimen
Patients must have had one prior systemic chemotherapeutic regimen for management of persistent, recurrent or metastatic carcinoma of the cervix (e.g.; paclitaxel/cisplatin, paclitaxel/cisplatin/bevacizumab); chemotherapy administered concurrent with primary radiation (e.g.; weekly cisplatin) is not counted as a systemic chemotherapy regimen; adjuvant chemotherapy given following the completion of radiation therapy (or concurrent chemotherapy and radiation therapy) is not counted as a systemic chemotherapy regimen (e.g.; paclitaxel and carboplatin for up to  cycles); NOTE: patients who have received more than one prior regimen are NOT eligible
Patients must have received at least one prior regimen of chemotherapy for symptomatic multiple myeloma; patients may not have more than six () previous regimens of therapy for the disease; prior chemotherapy must have been completed at least  days prior to registration; for study purposes, a regimen is defined as follows:\r\n* An anti-myeloma therapy used at the time of initial diagnosis or documented disease progression which is given with the intent to decrease disease burden\r\n* Any maintenance therapy used after an Induction should be considered part of that Induction regimen\r\n* Use of any agent or combination of agents more than once during the patients disease history for separate documented disease progressions will be counted as separate regimens (e.g., if a patient receives lenalidomide/bortezomib at initial diagnosis and achieves response, but then progresses and receives lenalidomide/bortezomib after progression, these count as  separate regimens)\r\n* In cases of allogeneic or autologous stem cell transplant, the entire induction + stem cell mobilization + conditioning + planned maintenance should be considered one regimen
Patients that have received a chemotherapy regimen with stem cell support in the previous  months
Patients who have relapsed from their initial doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) or similar standard treatment regimen and have not received any other chemotherapy or salvage systemic treatment
Participants on an antiretroviral regimen should be receiving treatment that is in accordance with the current International acquired immune deficiency syndrome (AIDS) Society guidelines; the specific agents are at the discretion of the investigator and use of agents currently available on an expanded access basis is allowed but use of experimental antiretroviral agents or those containing zidovudine (including Combivir and Trizivir) are prohibited; changes to highly active anti-retroviral therapy (HAART) therapy may be made if medically necessary (toxicity, failure of regimen, etc.); antiretroviral nave participants: participants who are not on HAART at study entry MUST begin therapy (utilizing the above guidelines) AFTER one cycle of chemotherapy has been completed under protocol; changes to HAART therapy may be made if medically necessary (toxicity, failure of regimen, etc.); concurrent therapy with zidovudine or a zidovudine-containing regimen (including Combivir and Trizivir) will be prohibited until  months following the participants completion of chemotherapy as part of this protocol; the use of cobicistat (e.g., Tybost), or cobicistat containing single tablet regimens (e.g., Stribild) is prohibited during concurrent chemotherapy under this protocol; participants taking cobicistat or cobicistat-containing single table regimens must switch to a different agent or regimen prior to enrollment, and will remain on the regimen until at least  months following treatment discontinuation; Cobicistat is a pure and potent cytochrome P, family , subfamily A, polypeptide  (CYPA) inhibitor and has the potential to increase the area under the curve (AUC) of CYPA substrates; therefore, both vincristine and doxorubicin would have the potential for drug drug interaction (DDI) with cobicistat since they are CYPA substrates
For advanced (stage III/IV) Hodgkin's disease, patients must have failed an adriamycin containing regimen (ABVD) or an alternative non-cross resistant regimen (e.g. MOPP)
Patients who have received more than one previous regimen of chemotherapy (maintenance is not considered a second regimen)
Eligible for treatment with a taxane-containing regimen (for example, docetaxel), unless taxane-containing regimen was declined after an informed decision
Must have received > or =  prior treatment regimen.
If the subject has DLBCL, there is no curative option with conventional therapy and the prior treatment included ?  prior combination chemoimmunotherapy regimen.
Have received more than one prior systemic chemotherapy regimen for metastatic disease.
A prior line of treatment is considered an induction regimen if it involves an approved or investigational cytotoxic chemotherapy agent, biological agent, and/or hypomethylating agent administered alone or in a combination regimen, with the intent to induce robust cytoreduction (i.e., CR).
A prior line of treatment is considered an induction regimen if it involves an approved or investigational cytotoxic chemotherapy agent, biological agent, and/or hypomethylating agent administered alone or in a combination regimen, with the intent to induce robust cytoreduction (i.e., CR).
Must be eligible to receive second-line standard-of-care chemotherapy with either ) an oxaliplatin-based chemotherapy regimen, or ) an irinotecan-based chemotherapy regimen
Patients must have received as a minimum a first line chemotherapy regimen consisting of at least  of the following agents: doxorubicin, cyclophosphamide, ifosfamide, etoposide.
Patients must have had one and only one prior regimen of systemic therapy for metastatic disease unless the patient meets the criteria below
For RCC, at least two prior anticancer regimens (one must be a VEGF-targeted TKI), or are otherwise inappropriate candidates for all approved therapies. For OCCC, at least one line of prior therapy with a platinum and taxane regimen.
Carmustine ?  mg/m received as part of the pre-transplant conditioning regimen
The subject has received at least  line of therapy in the metastatic or locally advanced disease setting. The subject has been documented to have progressed by determination of the investigator on a regimen containing an anti-HER agent as the most recent regimen or the most recent anti-HER regimen was discontinued for any toxicity, with the exception of a cardiotoxicity.
Patients must have relapsed after having achieved at least stable disease for at least one cycle of treatment to at least one prior regimen and then developed PD.
Group A at least one prior regimen of therapy
Tumor relapse/progression within  months of completion of a cisplatin-based chemoradiotherapy regimen for the treatment of early stage tumors
Documentation of recurrent or progressive GBM following at least one () prior therapeutic regimen including upfront radiation and chemotherapy with temozolomide; up to three additional therapeutic regimens for disease progression prior to enrollment to the study is permitted
Experimental therapies when given as separate regimen are considered as separate line of therapy
For patients with relapsed/refractory disease: patients may have previously received chemotherapy with a mitoxantrone- or cladribine-based regimen for MDS or AML; if that patient has received G-CLAM before and has been sensitive to this regimen, eligibility will be determined on a case-by-case basis by the study principal investigator (PI)
Subject must have received ?  prior treatment regimen(s)
Required drainage of ascites during the final  cycles of their last platinum-based regimen and/or during the period between the last dose of chemotherapy of that regimen and randomization to maintenance treatment in this study.
Patients with no prior therapy for WM, must be considered inappropriate candidates for treatment with a standard chemoimmunotherapy regimen
Receive only RIC regimen (i.e. Regimen A)
Receipt of >  mg/m^ total dose of carmustine (BCNU) with prior treatments including transplant conditioning regimen
Progression of disease after the most recent anticancer treatment. At least  prior chemotherapy regimen must have included a taxane.
Participants must have received at least one prior platinum-based regimen for advanced cholangiocarcinoma and had progressive disease or become intolerable to the regimen
Previous treatment with CLAG or other chemotherapy regimen containing both cladribine and cytarabine
Patients must have received at least one prior systemic chemotherapy regimen for metastatic pancreatic cancer; they should have experienced disease progression or intolerable toxicity from that regimen
Stable prescription of analgesic regimen during the  weeks prior to randomization.
Use of a systemic treatment regimen for metastatic disease within  days preceding the first dose of AEB and BYL
Diabetics on a stable dose of insulin or antihyperglycemic regimen are allowed if they have had no prior seizures and no history of loss of consciousness due to hypoglycemia
Most recent treatment regimen for metastatic disease must include Trastuzumab and chemotherapy.
Note: Trastuzumab emtansine (T-DM) is considered acceptable as prior Trastuzumab/chemotherapy regimen
Documented relapse or progressive disease on or after any regimen (subjects refractory to the most recent regimen are eligible)
For patients to be treated with a regimen containing -fluorouracil/leucovorin:
For patients to be treated with a regimen containing capecitabine:
For patients to be treated with a regimen containing irinotecan:
Previously treated with - lines of therapy (example: completed greater than or equal to [>/=]  treatment cycles per therapy), including at least one standard chemotherapy-containing regimen
For participants with the p deletion, previously treated with - lines of therapy, including at least one prior standard chemotherapy-containing regimen or at least one prior alemtuzumab-containing therapy
Not appropriate for treatment with a purine-based analogue regimen (per National Comprehensive Cancer Network [NCCN] or European Society for Medical Oncology [ESMO] guidelines), including relapse ?  months from a purine-based chemoimmunotherapy regimen or relapse ?  months from a purine-based monotherapy regimen
Patients must have prior treatment with >=  cycles of lenalidomide and >=  cycles of bortezomib (either in separate regimens or as part of the same regimen) (primary refractory of subjects refractory to the most recent regimen are eligible)
Received > prior anti-cancer drug regimen for advanced or metastatic NSCLC. Patients who develop disease progression while on switch maintenance therapy (maintenance using an agent not in the first-line regimen) will not be eligible.
Patients who have had drainage of their ascites during the final  cycles of their last chemotherapy regimen prior to enrolment on the study.
Must have received at least  prior platinum-based chemotherapy regimen but have received no more than  lines of prior chemotherapy regimens, with no limit to the number of lines of prior hormonal therapy. Front-line therapy may include neoadjuvant and adjuvant therapy and will be counted as  prior systemic regimen. Biological therapy (e.g. bevacizumab) administered as a single agent is considered a prior systemic regimen and not a prior chemotherapy regimen. Maintenance therapy is not considered its own regimen but should be included with the regimen that it follows.
Patients that have received a chemotherapy regimen with stem cell support in the previous  months
Received > prior anti-cancer drug regimen for advanced or metastatic NSCLC. Patients who develop disease progression while on switch maintenance therapy (maintenance using an agent not in the first-line regimen) will not be eligible.
At least  prior chemotherapy regimens; at least one fludarabine or other nucleoside analog containing regimen; chemotherapy in combination with monoclonal antibody (Rituxan) will be considered one prior regimen, but single agent Rituxan will not be considered one prior regimen; single agent ofatumumab will be counted as a regimen
Age criteria:\r\n* High dose TBI regimen:  months to =<  years \r\n* Middle intensity TBI regimen:  months to =<  years\r\n* Conditioning regimen selection should be based on the underlying disease, presence of minimal residual disease (MRD), age, co-morbidities, attending physician, and site preference; conditioning regimen will not require stratification of the randomization due to heterogeneity in the cohort of eligible patients.
Relapsed after ?  prior chemotherapy regimens, including the following: First-line treatment with standard anthracycline-containing regimen (e.g., cyclophosphamide, doxorubicin, vincristine, and prednisone or equivalent). At least  additional combination chemotherapy regimen. Patients relapsed after or refractory to first prior chemotherapy- and/or immunotherapy-based regimen for aggressive NHL and not eligible for high-dose regimen followed by transplant. High-dose chemotherapy, or chemoradiotherapy with autologous stem cell transplantation is considered  regimen. Patients with CD expressing neoplastic cells must have received prior rituximab, if available.
Patients with primary AML should have received no more than two () prior cytotoxic containing salvage regimens. Reinduction with the same regimen or stem cell transplant will not be considered a separate salvage regimen. Change of drugs will be considered a salvage regimen. Unlimited FLT TKI therapy (even in combination with cytotoxics/hypomethylating agents) is allowed for patients enrolled in cohort B
For patients with HL or ALCL, subjects are eligible after failure of at least one prior multi-agent chemotherapy regimen
Patients previously treated with a bendamustine-containing regimen who did not achieve a response or who relapsed and required treatment within  months of treatment with that regimen
Patients must have received at least one chemotherapy regimen which contained doxorubicin.
Patients with breast cancer must have had at least one prior chemotherapy regimen for metastatic disease; additionally, patients with breast cancer must have received prior tamoxifen and/or aromatase inhibitor therapy (if post-menopausal) with at least one hormonal regimen in the metastatic setting; patients with HER+ breast cancer must have progressed after at least one prior HER-directed regimen (trastuzumab, lapatinib) for metastatic disease\r\n* All other patients must have disease that has progressed following at least one line of standard therapy; prior therapy with tamoxifen is allowed
Patients had at least one prior regimen consisting of at least  cycle
Subjects must have recurrent, unresectable, or metastatic cervical cancer and have relapsed after a platinum-containing doublet administered for treatment of advanced (recurrent, unresectable, or metastatic) disease. Subjects must have persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma of the cervix, with documented disease progression (disease not amenable to curative therapy). Note: The following cervical tumors are not eligible: minimal deviation/adenoma malignum, gastric type adenocarcinoma, clear cell carcinoma and mesonephric carcinoma. Histologic confirmation of the original primary tumor is required via pathology report. Subjects must have had one prior systemic chemotherapeutic regimen for management of persistent, recurrent, or metastatic carcinoma of the cervix (e.g., paclitaxel/cisplatin, paclitaxel/cisplatin/bevacizumab). Chemotherapy administered concurrently with primary radiation (e.g., weekly cisplatin) is not counted as a systemic chemotherapy regimen. Adjuvant chemotherapy given following completion of radiation therapy (or concurrent chemotherapy and radiation therapy) is not counted as a systemic chemotherapy regimen (e.g., paclitaxel and carboplatin for ? cycles). Note: Subjects who have received > prior regimen are not eligible.
Patients who have received more than one chemotherapy regimen for metastatic disease
Patients with more than one previous chemotherapy regimen
Chronic lymphocytic leukemia (CLL) must have either \r\n * ) Failed to meet National Cancer Institute (NCI) Working Group criteria for complete or partial response after therapy with a regimen containing FLU (fludarabine phosphate) (or another nucleoside analog, e.g. -chlorodeoxyadenosine [-CDA], pentostatin) or experience disease relapse within  months after completing therapy with a regimen containing FLU (or another nucleoside analog) \r\n * ) Failed FLU- CY (cyclophosphamide)-rituximab (FCR) combination chemotherapy at any time point; or \r\n * ) Have \p deletion\ cytogenetic abnormality and relapsed at any time point after any initial chemotherapy
a purine analog-containing regimen
a bendamustine-containing regimen
a chlorambucil-containing regimen
an alemtuzumab-containing regimen (for those subjects with a p deletion)
At least  prior antineoplastic chemotherapy treatment regimen for metastatic disease and at least  prior treatment with a trastuzumab-containing regimen for at least  weeks, for metastatic disease or subject relapsing under adjuvant treatment (part  only).
Prolymphocytic leukemia (PLL), T-cell chronic lymphocytic lymphoma (T-CLL)\r\n* T-PLL: treatment failure after Campath-H and at least one other regimen\r\n* B-PLL: treatment failure after fludarabine and at least one other salvage regimen
Left ventricular ejection fraction of at least % (myeloablative regimen , reduced intensity regimen ) or % (nonmyeloablative regimen )
Creatinine < . mg/dL (myeloablative regimen , reduced intensity regimen ) or < . mg/dL (nonmyeloablative regimen )
Serum glutamate pyruvate transaminase (SGPT) =< to . x normal (myeloablative regimen , reduced intensity regimen ) or =< . x normal (nonmyeloablative regimen )
Bilirubin =< to . x normal (myeloablative regimen , reduced intensity regimen ) or =< . x normal (nonmyeloablative regimen )
Patients with B-Cell CLL or PLL who:\r\n* Failed to meet National Cancer Institute (NCI) Working Group criteria  for complete or partial response after  cycles of therapy with regimen containing fludarabine (or another nucleoside analog, e.g. cladribine [-CDA], pentostatin) or with disease relapse within  months after completing therapy with a fludarabine (or another nucleoside analog) containing regimen\r\n* Failed FCR or pentostatin/cyclophosphamide/rituximab (PCR) combination chemotherapy at any time point\r\n* Patients with novo or acquired p deletion cytogenetic abnormality; patients should have received induction treatment but could be transplanted in st CR
More than one prior treatment regimen for ALL or LL
Has experienced failure of at least  prior chemotherapy regimen:
Must have previously received at least one prior chemotherapeutic regimen for RT.
Progression on irinotecan containing regimen
Participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications, when clinically indicated and should be under the care of a physician experienced in HIV management; participants will be eligible regardless of antiretroviral medication (including no antiretroviral medication) provided there is no intention to initiate therapy or the regimen has been stable for at least  weeks with no intention to change the regimen within  weeks following study entry; as study-specific (antiretroviral-based) strata fill, however, only participants who are receiving the therapies eligible for the remaining open strata will be accrued
Participants must be on a stable antiretroviral regimen per current International Acquired Immunodeficiency Syndrome (AIDS) Society guidelines as follows, with no intention of changing the regimen within  weeks after ibrutinib initiation:\r\n* Choice of regimen: The specific antiretroviral agents are at physician discretion, and the use of investigational agents currently available on an expanded-access basis is allowed; use of experimental antiretroviral agents or those containing zidovudine (including Combivir and Trizivir) is prohibited\r\n* Patients with mantle cell lymphoma, CLL, or SLL must be on non-cytochrome P, family , subfamily A, polypeptide  (CYPAA) modulating antiretroviral agents (Stratum C) to be eligible for this study\r\n* Patients may be switched to non-conflicting regimens in order to participate\r\n* Stability of regimen: With the exception of patients on zidovudine-based ART, any changes in antiretroviral regimen must be made at least  weeks prior to ibrutinib initiation; patients taking zidovudine-based ART must change to a non-zidovudine-based regimen at least  weeks prior to ibrutinib initiation; changes to ART therapy during the study may be made if medically necessary (e.g. toxicity, treatment failure)
Treatment with more than one prior chemotherapy regimen
MESOTHELIOMA COHORTS (COHORTS  AND  ONLY): Patients must have had at least one prior chemotherapy regimen, with the Food and Drug Administration (FDA)-approved regimen of a platinum-based therapy in combination with pemetrexed being preferred unless there was a specific contraindication for an individual patient; there is no limit to the number of prior chemotherapy regimens received
ERLOTINIB HYDROCHLORIDE ARM: Patients with SCLC or thymic malignancies must have been treated with at least  previous standard of care chemotherapy regimen or refuse to be treated with conventional chemotherapy agents
SELUMETINIB ARM: Patients must have been treated with at least  previous standard of care chemotherapy regimen or refuse to be treated with conventional chemotherapy agents
AKT INHIBITOR MK ARM: Patients must have been treated with at least  previous standard of care chemotherapy regimen or refuse to be treated with conventional chemotherapy agents
LAPATINIB DITOSYLATE ARM: Patients must have been treated with at least  previous standard of care chemotherapy regimen or refuse to be treated with conventional chemotherapy agents
SUNITINIB MALATE ARM: Patients must have been treated with at least  previous standard of care chemotherapy regimen or refuse to be treated with conventional chemotherapy agents
Patients with relapsed chronic lymphocytic leukemia with high risk features: lack of objective response or relapse within  months following nucleoside-analogue based chemotherapy regimen or patients with p deletion CLL who lacked objective response to at least  preceding chemotherapy regimen
Patients with malignant pleural disease (MPD), pathologically confirmed at Memorial Sloan-Kettering Cancer Center (MSKCC) (radiographic confirmation is acceptable for screening phase eligibility), and defined as one of the following (patients who have not yet received treatment may enroll in the screening portion only):\r\n* Malignant pleural mesothelioma  previously treated with at least one prior treatment regimen\r\n* Non-small cell lung cancer metastatic to the pleurapreviously treated with at least one prior treatment regimen (chemotherapy, surgery, or targeted agent) and documented progression of disease; patients with disease outside of the pleura will be discussed among study principal investigator (PI) and Co-Pls prior to considered eligible for the study; disease outside of the pleura must not require any immediate therapy per PIs discretion\r\n* Breast cancer metastatic to the pleura previously treated with at least one prior treatment regimen (chemotherapy, surgery or targeted agent) and documented progression of disease; patients with disease outside of the pleura will be discussed among study PI and Co-Pls prior to considered eligible for the study; disease outside of the pleura must not require any immediate therapy per PIs discretion
Any of the following as this regimen may be harmful to a developing fetus or nursing child:
More than  prior chemotherapy regimen (a subject who received first- line carboplatin and taxane and then receives the same taxane second- line will be considered to have had  prior chemotherapy regimen)
Less than three weeks since the last chemotherapy-containing regimen
Prior treatment with a trastuzumab containing chemotherapy regimen is required.
A) Dose Escalation Stage: Confirmed diagnosis of relapsed or refractory Non-Hodgkin Lymphoma (NHL) treated with prior treatment for lymphoid malignancy comprising of at least  regimen containing a therapeutic anti-CD antibody (eg, rituximab, ofatumumab, GA-) and at least  prior combination chemotherapy regimens (or autologous stem cell transplant) , or treated with  prior combination chemotherapy regimen in patients without an approved second-line therapy option, requiring treatment in the opinion of the treating physician
Expansion Cohort A: Relapsed or refractory DLBCL treated with prior treatment for lymphoid malignancy comprising of at least  regimen containing a therapeutic anti-CD antibody (eg, rituximab, ofatumumab, GA-) and at least  prior combination chemotherapy regimens or autologous stem cell transplant, or treated with  prior combination chemotherapy regimen in patients without an approved second-line therapy option, requiring treatment in the opinion of the treating physician
Expansion Cohort B: Diagnosis of relapsed or refractory B-cell NHL (other than DLBCL) treated with prior treatment for lymphoid malignancy comprising of at least  regimen containing a therapeutic anti-CD antibody (eg, rituximab, ofatumumab, GA-) and at least  prior combination chemotherapy regimens or autologous stem cell transplant, or treated with  prior combination chemotherapy regimen in patients without an approved second-line therapy option, requiring treatment in the opinion of the treating physician
Received at least  cycles of a bortezomib-containing regimen and  cycles of a lenalidomide-containing regimen, unless intolerant to these agents (defined as requiring discontinuation due to toxicity).
>  prior regimen
Patients must have received at least  prior treatment regimens, including bortezomib and an IMiD (e.g., lenalidomide, thalidomide, pomalidomide). Induction therapy and stem cell transplant  maintenance are to be considered as a single regimen.
Previously received one or more lines of therapy including at least one CD-directed regimen (either as monotherapy or as chemoimmunotherapy) with documented failure to achieve at least PR or documented PD after, the most recent systemic treatment regimen
Bevacizumab-nave patients: these patients may not have more than one prior relapse not counting the current relapse being treated by this protocol and must have received at least one prior chemotherapy regimen, which must have included temozolomide
For the Phase b portion of the study, more than  prior chemotherapy regimens and for the Phase  portion of the study more than  prior chemotherapy regimens. Maintenance therapy following induction chemotherapy does not count as a separate regimen. In addition, hormonal therapy (e.g., tamoxifen or an aromatase inhibitor) does not count as a separate regimen.
Pregnant or lactating in female patients, if applicable (childbearing potential who have received a reduced intensity conditioning regimen)
Any prior chemotherapy must have been completed >=  weeks prior to day  of study treatment and the participant must have recovered to eligibility levels from prior toxicity\r\n* Only one prior regimen is allowed for relapsed AML patients; note one prior regimen is defined as follows:\r\n** Induction chemotherapy followed by consolidation is considered one regimen\r\n** Induction chemotherapy followed by re-induction in case of persistent disease followed by consolidation is considered one regimen\r\n* Hydroxyurea is allowed prior to day  of study treatment to keep white blood cell (WBC) below  K
Patients with transformed CTCL eligible for CHOP regimen
May have received ? prior systemic chemotherapy regimen for metastatic disease.
Subjects must not have had more than  previous treatment regimen with chemotherapy, interferon, or IL- for metastatic melanoma
More than  prior systemic regimen (prior MET inhibitors/antibodies are not allowed; experimental systemic therapy for inoperable HCC given before or after sorafenib counts as separate regimen and is not allowed)
Expected to receive ondansetron as part of antiemetic regimen (Cycle ); Expected to receive a -HT antagonist as part of antiemetic regimen (Cycles -)
If the participant has received prior bendamustine, response duration must have been greater than (>)  year (for participants who have relapse disease after a prior regimen)
Metastatic breast cancer patients must have received a minimum of  and a maximum of  prior anti HER based regimens with documented progression on the most recent regimen which must contain trastuzumab, ado-trastuzumab emtansine or lapatinib
Metastatic gastric cancer patients must have received a minimum of  and a maximum of  prior anti HER based regimens with documented progression on the most recent regimen which must contain trastuzumab or ado-trastuzumab emtansine
Patients must have at least one prior trastuzumab-containing regimen
On a stable parental study regimen (at least one cycle for the regimen at the dose/schedule that is to be given in the Treatment Extension study must have been given prior to the patient's discontinuation from the parental study). Signed written informed consent.
All patients must be prescribed combination antiretroviral therapy with the goal of virological suppression using an acceptable regimen that adheres to national guidelines for treatment of HIV infection; non-suppressed, treatment experienced patients, defined as patients with a viral load >  copies/mL who have been on antiretroviral therapy for more than  months can be enrolled if an alternative ART regimen is available that includes at least two ART drugs that, in the opinion of the site investigator, are expected to have activity based on genotypic testing (if available) and treatment history
Prior cell transfer therapy which included a myeloablative chemotherapy regimen (i.e.  total body irradiation [TBI] or  TBI plus chemotherapy)
At least  prior specific therapeutic regimen, one of which should have included rituximab (patients previously eligible for transplantation: the salvage treatment followed by intensification and Autologous Stem Cell Transplant (ASCT) will be considered one regimen).
Have received or refused at least one chemotherapy regimen
Recipient must demonstrate ability to be compliant with medical regimen.
Recipient must have no evidence of active infection at the time of the transplant preparative regimen or at time of transplantation.
Documentation for inclusion criteria histologically proven, unresectable, locally advanced or metastatic liposarcoma (dedifferentiated, myxoid round cell, or pleomorphic) or leiomyosarcoma. Participants must have a pathology report indicating the diagnosis of liposarcoma or leiomyosarcoma that has been reviewed by the sponsor before randomization may occur and treated in any order with at least: an anthracycline and ifosfamide containing regimen, or an anthracycline containing regimen and  additional cytotoxic chemotherapy regimen do not need to be reviewed by the Sponsor
Participating patients must receive medically appropriate care and treatment for HIV infection, including antiretroviral medications, when clinically indicated, and should be under the care of a physician experienced in HIV management; with the exception of treatment with zidovudine and stavudine, patients will be eligible regardless of antiretroviral regimen (no antiretroviral therapy, nonnucleoside reverse transcriptase inhibitors [NNRTI]-based therapy, or protease inhibitor based therapy), provided there is no intention to initiate therapy or the regimen has been stable for at least  weeks with no intention to change the regimen within  weeks following study entry; the exact regimen used for HIV therapy will be captured on Case Report Forms; as study-specific (antiretroviral therapy-based) strata fill, however, only patients fitting the remaining open strata will be accrued
Has received ?  prior chemotherapy regimens in any setting (a regimen is defined as any agent[s] that has been administered for more than  cycle; sequential neoadjuvant/adjuvant treatment is considered  regimen)
Patients with recurrent or progressive advanced stage NSCLC (no small cell lung cancer [SCLC] component) who have been treated with at least one and a maximum of two prior chemotherapy regimens for advanced NSCLC; chemotherapy as part of initial potentially curative therapy (given as part of adjuvant or concomitant chemoradiotherapy) that was completed <  year counts as  prior regimen; prior erlotinib, other EGFR tyrosine-kinase inhibitors (TKIs) or monoclonal antibodies targeting EGFR are not allowed; NOTE: Chemotherapy as part of initial potentially curative therapy (given as part of adjuvant or concomitant chemoradiotherapy) that was completed one or more years prior to screening for this study does not count as a prior regimen; if the tumor is refractory (progressed) after a prior chemotherapy regimen, then that regimen would count; if a prior chemotherapy regimen has been changed due to other reasons than disease progression (e.g. poor tolerance, allergic reaction), then it would not count as a separate prior regimen; a chemotherapy drug added for maintenance following disease stabilization or response to a chemotherapy regimen (in the absence of prior disease progression) does not count as a separate prior regimen; NOTE: Pathology reports documenting the diagnosis of NSCLC are required to be reviewed by the screening physician investigator
Suitable for either treatment regimen.
Subjects must be discontinued from ipilimumab or nivolumab as monotherapy or with the combination regimen
Prior systemic anticancer therapy: Patients will have received at least  platinum-based chemotherapy regimen, but no more than  cytotoxic chemotherapy regimens in the setting of recurrent or metastatic disease; the regimen(s) may have included biological, molecularly targeted or immune therapies; adjuvant chemotherapy is considered  cytotoxic chemotherapy regimen if the last administration occurred <  year prior to entry
Be scheduled to receive a single-day chemotherapy regimen that contains doxorubicin and/or cyclophosphamide and/or carboplatin; Herceptin (trastuzumab) and other chemotherapy agents will be allowed with any of these regimens
Be scheduled to receive an antiemetic regimen that does not contain Akynzeo; in addition, the antiemetic regimen must conform with American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines at cycle 
Plan to start a new cancer treatment regimen within  weeks from time of baseline registration; the treatment regimen is up to the discretion of the treating oncology physician; the regimen must include a chemotherapy drug or other agents that have similar prevalence of toxicity; patients who will receive monoclonal antibody therapy or other cancer therapies (e.g., tyrosine kinase inhibitors) are eligible if the other agents present a prevalence of toxicity similar to chemotherapy; these therapies can be used in combination with chemotherapy, as a single agent, or in combination with each other\r\n* Chemotherapy will be defined as cytotoxic drugs; in addition, agents (e.g., monoclonal antibodies and targeted agents) that have a prevalence of grade - toxicity in older patients similar to chemotherapy (> %) will be allowed; a list of allowable agents (single and in combination) meeting this toxicity criteria will be available on the University of Rochester Cancer Center (URCC) NCORP Research Base website as part of the study materials; given the rapidly changing landscape of new drugs for cancer, the study team led by the principal investigator (PI) will update the list accordingly after reviewing the toxicity profile of new therapies; if the potentially eligible participant is to receive an approved drug or regimen not on the list, contacting the URCC NCORP Research Base study team is required for approval prior to participant enrollment\r\n* Patients who are receiving approved cancer treatment in combination with radiation are eligible\r\n* A patient may also be enrolled on a treatment trial and participate in this study, if all other inclusion and exclusion criteria are met
Must be starting a new chemotherapy regimen (patients whose treatment regimen includes an immunomodulatory agent such as lenalidomide or small molecule targeted agents such as ibrutinib or idelalisib will be included in the study; patients being treated with a single agent monoclonal antibody will not be included)
Patients on ongoing chemotherapy regimen at the time of eligibility:
BC patients scheduled to undergo chemo regimen other than the -week, -week, -week, -week, or -week regimen
Prior treatment with > chemotherapy regimen for metastatic disease
Preparative regimen: both reduced intensity and ablative regimens are permitted; each center will pre-specify the regimen they intend to use during the conduct of the study
Subjects who have taken a neurokinin antagonist within  days prior to beginning the BEAM regimen
Scheduled to start a new treatment regimen for MBC, but no more than  previous chemotherapy regimens
Planned chemotherapeutic regimen for subject must meet all of the following criteria:\r\n* A known myelosuppressive regimen which includes a combination of at least two of the following agents: actinomycin, carboplatin, cisplatin, cyclophosphamide, daunorubicin, doxorubicin, etoposide, ifosfamide, topotecan\r\n* At least  consecutive cycles\r\n* Cycle length is either  or  days\r\n* Regimen must either alternate chemotherapeutic agents in an X-Y-X-Y format, such that the same chemotherapy is given every other cycle (e.g. vincristine/doxorubicin/cyclophosphamide | ifosfamide/etoposide), or repeat the same chemotherapeutic agents each cycle in an X-X-X-X format (e.g. repeated cycles of cisplatin/etoposide/bleomycin); questions regarding whether or not a patients chemotherapy plan meets inclusion criteria will be decided by the study chair
Planned to initiate a new systemic chemotherapy regimen (including patients starting on first chemotherapy or patients previously treated but starting on a new regimen)
Treatment plan to receive standard cisplatin monotherapy administered either every three weeks (- mg/m for  doses) or weekly (- mg/m for - doses). The decision on which chemotherapy regimen to use in combination with IMRT and GC will be at the discretion of the investigator.
Starting a new treatment regimen that includes a single oral anticancer medication
At least one prior chemotherapeutic regimen for advanced metastatic/recurrent disease, of which at least one regimen included a platinum agent (unless contraindicated)
Patients may receive up to  doses of aerosolized ribavirin (modified regimen) before enrollment into the study
No prior trastuzumab or anthracyclines prior to this chemotherapy regimen
Treated with any established chemotherapy regimen based on either:
Have a plan to receive a standard cisplatin chemotherapy regimen administered weekly (- mg/m) or approximately every  days (- mg/m)
Chemotherapy regimen: Doxorubicin/cyclophosphamide. Antiemetic regimen: Aprepitant + palonosetron + dexamethasone on Day  and aprepitant + dexamethasone on Days  & .
Chemotherapy regimen: Doxorubicin/cyclophosphamide/docetaxel. Antiemetic regimen: Aprepitant + palonosetron + dexamethasone on Day  and aprepitant + dexamethasone on Days  & .
Chemotherapy regimen: Docetaxel/carboplatin. Antiemetic regimen: Palonosetron on Day  + dexamethasone on Days , , & .
Chemotherapy regimen: Docetaxel/cyclophosphamide. Antiemetic regimen: Palonosetron on Day  + dexamethasone on Days , , & . Note: Fosaprepitant will be allowed in place of aprepitant, and either granisetron or ondansetron, on one or more days, will be allowed in place of palonosetron.
Nonmyeloablative preparative regimen
ANNUAL SCREENING REGIMEN ELIGIBILITY CHECK
Completed an approved regimen of neoadjuvant or adjuvant therapy with an approved regimen that includes trastuzumab and at least four cycles ( weeks) of taxane-containing chemotherapy with plan for completion of one year of trastuzumab therapy.
Anti-thymocyte globulin as part of the conditioning regimen
Antithymocyte globulin (ATG) as part of the conditioning regimen
The Ewings sarcoma must have progressed following at least one standard prior chemotherapy regimen
Planned reduced intensity conditioning regimen (see eligible regimens in Table .a)
Receiving a stable dose of octreotide LAR as a part of a treatment regimen for >=  months
Pregnant women are excluded from participation due to inability to participate in required chemotherapy regimen
